Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GNI Group ( (JP:2160) ) has provided an update.
GNI Group Ltd. announced the completion of subject enrollment for the Phase 1 clinical trial of CG001419, a novel non-opioid pain product candidate developed by its subsidiary Cullgen. This trial marks a significant step in offering a new class of pain signal inhibitors that could provide safer and more effective treatment options for acute and chronic pain, with plans to advance to Phase 2 trials by early next year. The financial impact on the company’s current fiscal year is expected to be minimal.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2551.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. is a company involved in the pharmaceutical industry, focusing on developing innovative treatments. Its key subsidiary, Cullgen Inc., is engaged in creating novel non-opioid pain management solutions, addressing the growing demand for safer analgesics amid the opioid crisis.
Average Trading Volume: 1,455,556
Technical Sentiment Signal: Hold
Current Market Cap: Yen138.9B
For detailed information about 2160 stock, go to TipRanks’ Stock Analysis page.